Nippon Chemiphar Co., Ltd. (JP:4539)

:4539

4539

Nippon Chemiphar Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4539 full AI Analyst Report?

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,430.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)2.30K

Market Cap

¥6.14B

Enterprise Value¥16.74B

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)11.6

Beta0.27

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.21%

Share Statistics

EPS (TTM)34.21

Shares Outstanding4,261,420

10 Day Avg. Volume1,680

30 Day Avg. Volume2,300

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)0.28

Price to Sales (P/S)0.16

P/FCF Ratio-2.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manageable Leverage And Solid Capital StructureA debt-to-equity of ~0.94 and a 38.5% equity ratio indicate a balanced leverage profile and solid capitalization. This durable financial foundation supports R&D and manufacturing investments, provides borrowing capacity if needed, and reduces bankruptcy risk over the medium term.

Recovering Profitability And Improving MarginsThe move from loss to a positive net margin and a rising EBITDA margin reflects operational recovery and better cost control. Sustained margin improvement increases internal funding for pipelines and commercialization, strengthening long-term earnings quality if maintained.

Diversified Pharma Business Model And Manufacturing CapabilityRevenue from prescription drug sales combined with potential licensing and contract manufacturing provides multiple, structurally different cash sources. Manufacturing and licensing capabilities enable partnerships and incremental margins, cushioning revenue volatility over months.

Bears Say

Negative Operating Cash Flow And Free Cash Flow DeficitPersistent negative operating cash flow and a free cash flow deficit constrain the firm's ability to self-fund R&D, regulatory filings, and commercial expansion. Over a multi-month horizon this elevates reliance on external financing and pressures liquidity and strategic flexibility.

Inconsistent Revenue GrowthRevenue that alternates between decline and modest recovery undermines predictability for a pharma company with fixed manufacturing and commercialization costs. This variability risks margin swings and makes planning for launches and long-term investments more difficult.

Low Returns And Thin Net MarginsA low ROE and very thin net and EBIT margins signal limited profitability relative to capital invested. Structurally low returns reduce retained earnings for reinvestment, weaken competitive positioning over time, and may force trade-offs between growth and cash preservation.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1430.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥6.14B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 24 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jan 30, 2026. The company reported ¥34.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥34.21.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.21%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of ¥34.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.